3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
3
Terminated
1
No longer available
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neoplasms
2
Head and Neck Neoplasms
2
Waldenstrom Macroglobulinemia
1
Neuroblastoma
1
Mouth Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hodgkin Disease
1
Gliosarcoma
1
Glioblastoma
1
Carcinoma, Ovarian Epithelial
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
6
Isotretinoin
5
thymoglobulin
4
fludarabine phosphate
4
fludarabine
4
aldesleukin
4
Topotecan
4
Temozolomide
4
Melphalan
4
Irinotecan
4
Etoposide
4
ribociclib
3
Thiotepa
3
Interleukin-2
3
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
Busulfan
3
Bone Marrow Transplantation
3
Antilymphocyte Serum
3
temsirolimus
2
omburtamab I-131
2
dinutuximab
2
Vincristine
2
Tretinoin
2
TPI-287
2
Stem Cell Transplantation
2
Rituximab
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neuroblastoma
×
Fenretinide
×
Clear all
NCT02163356
2022-03-31
SPOC2013-001
South Plains Oncology Consortium
Phase 1
Terminated
4 enrolled